 |
2003 Press Releases
January 16
Sangamo BioSciences Chief Scientific Officer to Present at Keystone Symposium
January 21
Sangamo BioSciences and Purdue Pharma Announce ZFP Enabling Technology Agreement
January 29
Sangamo BioSciences Announces Fourth Quarter 2002 Teleconference
February 3
Sangamo BioSciences Announces the Appointment of J. Tyler Martin, M.D. as Vice President, Development
February 5
Sangamo BioSciences Reports 2002 Fourth Quarter and Year-End Financial Results
February 25
Sangamo BioSciences Announces Presentation at the BIO CEO & Investor Conference 2003
March 4
Sangamo BioSciences Announces Presentation at the Lehman Brothers Sixth Annual Global Healthcare Conference
March 18
Sangamo BioSciences Granted U.S. Patent Covering Regulation of Gene Expression Using Engineered Zinc Finger DNA-Binding Proteins
April 22
Sangamo BioSciences Announces First-Quarter 2003 Teleconference
April 29
Sangamo BioSciences Reports First-Quarter Financial Results
June 4
Sangamo BioSciences to Present Preclinical Data and Scientific Advances At the 2003 Annual Meeting of the American Society of Gene Therapy
June 9
Sangamo BioSciences Introduces ZFP-Mediated Gene Correction as a New Therapeutic Platform at American Society of Gene Therapy Meeting
June 9
Sangamo BioSciences Presents Results of Preclinical Animal Studies At American Society of Gene Therapy Meeting
June 11
Sangamo Collaborator Receives Award for Research in Vascular Medicine
June 25
Sangamo BioSciences to Present at the William Blair & Company 23rd Annual Growth Stock Conference
July 1
Sangamo Announces Research & Development Management Changes
July 21
Sangamo BioSciences Announces Second-Quarter 2003 Teleconference
July 28
Sangamo BioSciences Reports Second-Quarter Financial Result
September 17
Sangamo BioSciences Announces Presentation at the UBS Global Lifesciences Conference
October 14
Sangamo BioSciences Announces Presentation at the Rodman and Renshaw Techvest Healthcare Conference
October 21
Sangamo BioSciences Announces Third-Quarter 2003 Teleconference
October 28
Sangamo BioSciences Reports Third-Quarter Financial Results
November 4
Sangamo BioSciences Announces Presentation at The Wall Street Analyst Forum
December 9
Sangamo BioSciences' Partner Edwards Lifesciences Announces Status of the Phase I 'AVENGE' Clinical Trial
The use of Zinc Finger DNA Binding Protein Transcription Factors to avoid cdna Patents
December 17
Sangamo BioSciences Licenses Proprietary Oncolytic Vector Technology from Onyx Pharmaceuticals
|
|
|
